Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Peripheral Arterial Disease
Interventions: Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA); Drug · Behavioral · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypercholesterolemia
Interventions: bempedoic acid 180mg, placebo, evolocumab; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Hypertriglyceridemia
Interventions: MAR001, Placebo; Drug
Lead sponsor: Marea Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 26
States / cities: Anniston, Alabama • Mobile, Alabama • Little Rock, Arkansas + 23 more

Conditions: Hypercholesteremia
Interventions: Gemcabene; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Generalized Lipodystrophy
Interventions: mibavademab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: Hyperlipidemia
Interventions: Uncle Sam Cereal; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypercholesterolemia, Hyperlipidemia, Vitamin Deficiency, Obesity
Interventions: Fortified eggs, Intermittent fasting, Non-egg supplemented, Usual care diet; Dietary Supplement · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 50 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Abdominal Obesity, Insulin Resistance, Hypertriglyceridemia
Interventions: Acipimox, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Healthy, Hypercholesterolemia, Hypertension
Interventions: hemoglobin-transported nitric oxide; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 29
States / cities: Encino, California • Fresno, California • Oakland, California + 25 more

Conditions: Primary Dyslipidemia, Mixed Dyslipidemia
Interventions: pitavastatin, pravastatin; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 44
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 41 more

Conditions: Hypertriglyceridemia
Interventions: Lovaza, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 19 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Atorvastatin; Drug · Genetic
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy, Hypercholesterolemia
Interventions: Enlicitide Chloride, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and stable statin therapy, Stable statin therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more

Conditions: Hyperlipidemia
Interventions: Plant sterol, Placebo; Dietary Supplement
Lead sponsor: University of Manitoba; Other
Eligibility: 30 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Hyperlipidemia, Hypercholesterolemia, Coronary Heart Disease, Cardiovascular Disease
Interventions: Simvastatin; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 30 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Insulin-Dependent, Hypercholesterolemia
Interventions: Atorvastatin, Atorvastatin Placebo; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 10 Years to 20 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more

Conditions: Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
Interventions: Volanesorsen; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 5 more

Conditions: Atherosclerosis, Hypercholesterolemia
Interventions: Statins, HMG CoA; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 50 Years to 99 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperlipidemia
Interventions: Bococizumab (PF-04950615; RN316), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 155
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 115 more

Conditions: Hyperlipidemia
Interventions: 1-MNA, Placebo; Drug
Lead sponsor: Pharmena North America; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypercholesterolemia, Hyperlipidemia, Familial Combined
Interventions: colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 10
States / cities: Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more

Search by objective public record fields.

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

Genetic Influences on Statin Blood Concentrations in African Americans

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

A Controlled Trial of High Dietary Fiber Intake on Serum Lipids

PROSPective Evaluation of Fortified Eggs Related to Improvement in The Biomarker Profile for Your Health

Effects of Acipimox on Mitochondrial Function in Obesity

Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia

Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides

Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet

A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols

Cholesterol and Pharmacogenetic Study

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Safety of a Hypolipidemic Agent in Healthy Normal Volunteers

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol